SCHEMBL17714765

SCHEMBL17714765

c1ccc(-c2nc(-c3ccccc3)nc(-c3cc(-c4ccc5c(c4)c4ccccc4n5-c4ccc(-c5ccc6c7ccccc7n(-c7ccccc7)c6c5)cc4)ccn3)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 4/20 0.36
KMT2A Q03164 4/20 0.36
NPSR1 Q6W5P4 2/20 0.36
PTK2B Q14289 1/20 0.36
PTGER4 P35408 1/20 0.36
KHK P50053 2/20 0.34
CYP2C19 P33261 2/20 0.33
MEN1 O00255 2/20 0.33
ALDH1A1 P00352 2/20 0.33
AVPR1A P37288 1/20 0.33
HSP90AA1 P07900 1/20 0.33
PTPN1 P18031 1/20 0.33
TSHR P16473 1/20 0.33
NPY5R Q15761 1/20 0.33
TSPO P30536 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17714723 1.00 KDM4E (0.39) KDM4EATML3MBTL1MAPTKMT2A
SCHEMBL17714812 0.97 KDM4E (0.42) KDM4EATML3MBTL1MAPTKMT2A
SCHEMBL17714722 0.97 KDM4E (0.42) KDM4EATML3MBTL1MAPTKMT2A
SCHEMBL17915709 0.95 KDM4E (0.38) KDM4EATML3MBTL1MAPTKMT2A
SCHEMBL17714827 0.95 KDM4E (0.38) KDM4EATML3MBTL1MAPTKMT2A
SCHEMBL17714751 0.95 KDM4E (0.38) KDM4EATML3MBTL1MAPTKMT2A
SCHEMBL17714870 0.95 KDM4E (0.38) KDM4EATML3MBTL1MAPTKMT2A
SCHEMBL25835080 0.94 L3MBTL1 (0.44) KDM4EATML3MBTL1MAPTKMT2A
SCHEMBL17714800 0.91 KDM4E (0.41) KDM4EATML3MBTL1MAPTKMT2A
SCHEMBL17714898 0.91 KDM4E (0.41) KDM4EATML3MBTL1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11111231-B2 Heterocyclic compound and organic light-emitting device comprising same LG CHEM, LTD. (KR) 2021-09-07 US disclosed
EP-3015465-B1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LG CHEMICAL LTD (KR) 2019-09-04 EP disclosed
US-20190127352-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2019-05-02 US disclosed
US-10253016-B2 Heterocyclic compound and organic light-emitting device comprising same LG CHEM, LTD. (KR) 2019-04-09 US disclosed
US-20160204359-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2016-07-14 US disclosed
US-20160204359-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2016-07-14 US disclosed
EP-3015465-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LG Chem, Ltd. (KR) 2016-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10253016-B2 Heterocyclic compound and organic light-emitting device comprising same CRY1, CRY2, NR2E3 KDM4E 1531/4885ATM 2327/4885L3MBTL1 699/4885
US-20160204359-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CRY2, NR2E3 KDM4E 1531/4885ATM 2327/4885L3MBTL1 699/4885
US-11111231-B2 Heterocyclic compound and organic light-emitting device comprising same CRY1, CRY2, NR2E3 KDM4E 1531/4885ATM 2327/4885L3MBTL1 699/4885
US-20190127352-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CRY2, NR2E3 KDM4E 1531/4885ATM 2327/4885L3MBTL1 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.